Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
Revenue Growth AcceleratingAccelerating
Percentile Rank77
3Y CAGR-13.8%
5Y CAGR-6.4%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
-13.8%/yr
Quarterly compound
5Y CAGR
-6.4%/yr
Recent deceleration
Percentile
P77
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.89% |
| Q3 2025 | -9.81% |
| Q2 2025 | 2.36% |
| Q1 2025 | 7.71% |
| Q4 2024 | 9.08% |
| Q3 2024 | -13.53% |
| Q2 2024 | 1.30% |
| Q1 2024 | 0.18% |
| Q4 2023 | 3.35% |
| Q3 2023 | -8.36% |
| Q2 2023 | 4.08% |
| Q1 2023 | 14.08% |
| Q4 2022 | 15.43% |
| Q3 2022 | -0.58% |
| Q2 2022 | 4.56% |
| Q1 2022 | 9.95% |
| Q4 2021 | 14.62% |
| Q3 2021 | -4.04% |
| Q2 2021 | 4.13% |
| Q1 2021 | 4.04% |
| Q4 2020 | 13.74% |
| Q3 2020 | -1.08% |
| Q2 2020 | -16.80% |
| Q1 2020 | 3.24% |
| Q4 2019 | 4.27% |
| Q3 2019 | -5.09% |
| Q2 2019 | 4.83% |
| Q1 2019 | 3.01% |
| Q4 2018 | 6.94% |
| Q3 2018 | -7.05% |
| Q2 2018 | 12.24% |
| Q1 2018 | 7.16% |
| Q4 2017 | 10.20% |
| Q3 2017 | -14.32% |
| Q2 2017 | 7.53% |
| Q1 2017 | 10.76% |
| Q4 2016 | 25.08% |
| Q3 2016 | -15.86% |
| Q2 2016 | 5.72% |
| Q1 2016 | 1.22% |